Compare · DKDCA vs INCY
DKDCA vs INCY
Side-by-side comparison of Data Knights Acquisition Corp. (DKDCA) and Incyte Corp. (INCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DKDCA and INCY operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $22.96B, about 152.2x DKDCA ($150.9M).
- INCY has hit the wire 7 times in the past 4 weeks while DKDCA has been quiet.
- INCY has more recent analyst coverage (25 ratings vs 0 for DKDCA).
- Company
- Data Knights Acquisition Corp.
- Incyte Corp.
- Price
- $7.02+17.00%
- $113.12-0.12%
- Market cap
- $150.9M
- $22.96B
- 1M return
- -
- -11.36%
- 1Y return
- -
- +31.32%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest DKDCA
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- Data Knights Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- SEC Form S-1 filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Data Knights Acquisition Corp.
- New insider Casey Paul claimed ownership of 599,172 shares (SEC Form 3)
- New insider Kosasa Thomas claimed ownership of 4,952,409 shares (SEC Form 3)
- SEC Form NT 10-Q filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status
Latest INCY
- Incyte to Report Third Quarter Financial Results
- Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
- SEC Form 4 filed by Incyte Corp.
- Director Baker Bros. Advisors Lp was granted 644 shares (SEC Form 4)
- Director Clancy Paul J was granted 203 shares, increasing direct ownership by 0.79% to 25,838 units (SEC Form 4)
- Director Harrigan Edmund was granted 206 shares, increasing direct ownership by 0.89% to 23,225 units (SEC Form 4)
- MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
- EVP, Chief Strategy Officer Gardner David H covered exercise/tax liability with 920 shares, decreasing direct ownership by 5% to 15,904 units (SEC Form 4) to satisfy withholding tax
- Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio